天美影院

颁补谤谤颈猫谤别蝉Espace presseCOVID-19
  1. Home
  2. Imagerie M茅dicale
  3. Molecular Imaging
  4. MI Trends and Innovations
  5. xSPECT Quant
Isotope 123I xSPECT Quant brain

xSPECT QuantReliable SPECT/CT quantification for clinical routine

MI 10 year anniversary emblem
xSPECT Quant

Conventional SPECT/CT quantification is manual and time intensive鈥攐ften requiring specialized resources to manage the complexity and potential for error. As a result, quantitative SPECT/CT is rarely used clinically.

The only tool to offer automated, accurate, and reproducible quantification for a range of isotopes, xSPECT Quant鈩 has paved the way for routine SPECT/CT quantification.

xSPECT Quant uses a 3% National Institute of Standards and Technology (NIST) traceable precision source, which allows you to easily standardize uptake values across different cameras, dose calibrators, and facilities.

Accurate to within 5%,1聽xSPECT Quant is the industry鈥檚 most precise and reproducible1 SPECT/CT quantitative solution. Available for 99mTc, 123I, 177Lu, 111In, and 131滨听颈尘补驳颈苍驳,2聽xSPECT Quant enables clinical SPECT/CT quantification to more precisely detect disease and better manage therapy.

The absolute quantification capabilities of xSPECT Quant are also a basis for theranostics, the unique approach of combining diagnostics and therapy.

What experts say

鈥淨uantitative images are part of almost every study we do. This allows us to obtain more precise information for each patient. With quantitative data, we are starting to detect abnormalities earlier and tailor treatments.鈥

John Prior, PhD, MD, FEBNM Lausanne, Switzerland

John O. Prior, PhD, MD FEBNM

Professor and Head of Department of Nuclear Medicine and Molecular Imaging Lausanne, Switzerland

To learn more about theranostics visit SPECT/CT Quantification for theranostics.

Clinical image gallery

1/4
Isotope 123I 01
Isotope 111In
01
Isotope 177Lu
01
Isotope 99mTc
01
Isotope 123I

Isotope 123I

123I xSPECT Quant enables standardized quantification for appropriate diagnosis in equivocal motion disorders.

Isotope 123I
Isotope 111In
Isotope 177Lu
Isotope 99mTc
1/4

Case studies

1/4
99mTc01
177Lu01
111In01
123I01
Differentiation of a rib benign lesion from a metastasis using xSPECT Quant

Data courtesy of Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Differentiation of a rib benign lesion from a metastasis using xSPECT Quant

By Mario Jreige, MD; Patrick Omoumi, MD; John O. Prior, MD, PhD; and Marie Nicod Lalonde, MD

Differentiation of a rib benign lesion from a metastasis using xSPECT Quant
Sequential quantitative SPECT/CT following therapeutic administration of 177Lu DOTATATE in a patient with liver metastases from neuroendocrine tumor
Robust quantification of neuroendocrine tumor imaging: xSPECT Quant with 111In tracers enables new possibilities in SPECT/CT imaging
123I xSPECT Quant enables standardized quantification in unclear motion disorder
1/4

White paper

White paper
Data courtesy of Friedrich Alexander University, Erlangen, Germany.

Accurate, reproducible, and standardized quantification

Written by A. Hans Vija, PhD, Carl von Gall, MD, and Partha Ghosh, MD
Siemens Healthineers Molecular Imaging

1
Data on file.
2
xSPECT Quant 131I is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
The statements by Siemens Healthineers' customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.

Header image data courtesy of Centre Hospitalier Universitlair Vaudois, Lausanne, Switzerland.